State Street’s SAB Biotherapeutics SABS Stock Holding History

State Street’s Portfolio SABS Stock Details SABS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$284K	Buy	74,231 +61,109	+466%	+$244K	﹤0.01%	3801
2025 Q4	$49.1K	Buy	+13,122	New	+$43.2K	﹤0.01%	4151
2024 Q1	–	Sell	-8,124	Closed	-$55.9K	–	4398
2023 Q4	$55.9K	Hold	8,124	–	–	﹤0.01%	4177
2023 Q3	$51.2K	Hold	8,124	–	–	﹤0.01%	4284
2023 Q2	$67.4K	Hold	8,124	–	–	﹤0.01%	4330
2023 Q1	$35.7K	Hold	8,124	–	–	﹤0.01%	4586
2022 Q4	$47.9K	Hold	8,124	–	–	﹤0.01%	4567
2022 Q3	$57K	Hold	8,124	–	–	﹤0.01%	4628
2022 Q2	$118K	Buy	8,124 +3,890	+92%	+$81.7K	﹤0.01%	4449
2022 Q1	$159K	Buy	4,234 +3,004	+244%	+$139K	﹤0.01%	4467
2021 Q4	$96K	Buy	+1,230	New	+$115K	﹤0.01%	4590

Other funds holding SABS

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street's SABS Position: Q1 2026 in Review

State Street increased its SAB Biotherapeutics (SABS) stake by 466% in Q1 2026, buying an estimated $244K and bringing the position to 74,231 shares worth $284K. The position accounts for ﹤0.01% of the portfolio, ranked #3801.

State Street first reported a position in SABS in Q4 2021 and has held it in 11 quarters since. 76 funds tracked by Wall St. Rank hold SABS as of Q1 2026.

State Street held 74,231 shares of SAB Biotherapeutics worth $284K as of Q1 2026.
State Street bought 61,109 SAB Biotherapeutics shares in Q1 2026, an estimated $244K.
SAB Biotherapeutics made up ﹤0.01% of State Street's portfolio in Q1 2026, its #3801 holding.
State Street first reported a position in SAB Biotherapeutics in Q4 2021 and has held it in 11 quarters since.
76 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.